Rhumbline Advisers Theseus Pharmaceuticals, Inc. Transaction History

Rhumbline Advisers

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 08, 2024	BUY	$2.12 - $4.18 $19,497 - $38,443	9,197 Added 32.9%	37,155 $150,000
Q3 2023 Nov 09, 2023	BUY	$2.66 - $10.04 $1,758 - $6,636	661 Added 2.42%	27,958 $75,000
Q2 2023 Aug 08, 2023	BUY	$7.28 - $11.82 $10,738 - $17,434	1,475 Added 5.71%	27,297 $254,000
Q1 2023 May 11, 2023	BUY	$5.21 - $14.05 $4,272 - $11,521	820 Added 3.28%	25,822 $229,000
Q4 2022 Feb 14, 2023	BUY	$4.69 - $8.36 $722 - $1,287	154 Added 0.62%	25,002 $125,000

Q3 2022 Nov 10, 2022	BUY	$5.7 - $8.68 $8,225 - $12,525	1,443 Added 6.17%	24,848 $144,000
Q2 2022 Aug 11, 2022	BUY	$5.04 - $14.05 $117,961 - $328,840	23,405 New	23,405 $129,000

1.06M

Ticker THRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,713,400
Description
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also ...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.